Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Oct;48(10):890–895. doi: 10.1136/jcp.48.10.890

Steroid hormone receptors and their clinical significance in cancer.

R I Nicholson 1, R A McClelland 1, J M Gee 1
PMCID: PMC502940  PMID: 8537483

Full text

PDF
890

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battersby S., Robertson B. J., Anderson T. J., King R. J., McPherson K. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer. 1992 Apr;65(4):601–607. doi: 10.1038/bjc.1992.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blamey R. W., Bishop H. M., Blake J. R., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  3. Bonkhoff H., Remberger K. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993;422(1):35–38. doi: 10.1007/BF01605130. [DOI] [PubMed] [Google Scholar]
  4. Campbell F. C., Blamey R. W., Elston C. W., Nicholson R. I., Griffiths K., Haybittle J. L. Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer. 1981 Sep;44(3):456–459. doi: 10.1038/bjc.1981.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chalbos D., Philips A., Galtier F., Rochefort H. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells. Endocrinology. 1993 Aug;133(2):571–576. doi: 10.1210/endo.133.2.8344199. [DOI] [PubMed] [Google Scholar]
  6. Chambers J. T., MacLusky N., Eisenfield A., Kohorn E. I., Lawrence R., Schwartz P. E. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol. 1988 Sep;31(1):65–81. doi: 10.1016/0090-8258(88)90270-3. [DOI] [PubMed] [Google Scholar]
  7. Chawla A., Lazar M. A. Induction of Rev-ErbA alpha, an orphan receptor encoded on the opposite strand of the alpha-thyroid hormone receptor gene, during adipocyte differentiation. J Biol Chem. 1993 Aug 5;268(22):16265–16269. [PubMed] [Google Scholar]
  8. Colley M. H., Geppert E., Franklin W. A. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am J Surg Pathol. 1989 Sep;13(9):803–807. doi: 10.1097/00000478-198909000-00011. [DOI] [PubMed] [Google Scholar]
  9. Creasman W. T. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993 Feb 15;71(4 Suppl):1467–1470. doi: 10.1002/cncr.2820710411. [DOI] [PubMed] [Google Scholar]
  10. Davis I. J., Hazel T. G., Chen R. H., Blenis J., Lau L. F. Functional domains and phosphorylation of the orphan receptor Nur77. Mol Endocrinol. 1993 Aug;7(8):953–964. doi: 10.1210/mend.7.8.8232315. [DOI] [PubMed] [Google Scholar]
  11. Fahrner T. J., Carroll S. L., Milbrandt J. The NGFI-B protein, an inducible member of the thyroid/steroid receptor family, is rapidly modified posttranslationally. Mol Cell Biol. 1990 Dec;10(12):6454–6459. doi: 10.1128/mcb.10.12.6454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fuller P. J. The steroid receptor superfamily: mechanisms of diversity. FASEB J. 1991 Dec;5(15):3092–3099. doi: 10.1096/fasebj.5.15.1743440. [DOI] [PubMed] [Google Scholar]
  13. Fuqua S. A., Falette N. F., McGuire W. L. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst. 1990 May 16;82(10):858–861. doi: 10.1093/jnci/82.10.858. [DOI] [PubMed] [Google Scholar]
  14. Fuqua S. A., Fitzgerald S. D., Allred D. C., Elledge R. M., Nawaz Z., McDonnell D. P., O'Malley B. W., Greene G. L., McGuire W. L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15;52(2):483–486. [PubMed] [Google Scholar]
  15. Gower W. R., Jr Mechanism of glucocorticoid action. J Fla Med Assoc. 1993 Oct;80(10):697–700. [PubMed] [Google Scholar]
  16. Graham D. M., Jin L., Lloyd R. V. Detection of estrogen receptor in paraffin-embedded sections of breast carcinoma by immunohistochemistry and in situ hybridization. Am J Surg Pathol. 1991 May;15(5):475–485. doi: 10.1097/00000478-199105000-00008. [DOI] [PubMed] [Google Scholar]
  17. Gustafsson J. A., Dahlman-Wright K., Strömstedt P. E., Wright T., Carlstedt-Duke J. Structure-function aspects of the glucocorticoid receptor. Princess Takamatsu Symp. 1990;21:137–155. [PubMed] [Google Scholar]
  18. Henry J. A., Angus B., Horne C. H. Oestrogen receptor and oestrogen regulated proteins in human breast cancer: a review. Keio J Med. 1989 Sep;38(3):241–261. doi: 10.2302/kjm.38.241. [DOI] [PubMed] [Google Scholar]
  19. Howell A., Harland R. N., Barnes D. M., Baildam A. D., Wilkinson M. J., Hayward E., Swindell R., Sellwood R. A. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res. 1987 Jan 1;47(1):300–304. [PubMed] [Google Scholar]
  20. Hutter R. V. The role of the pathologist in breast cancer management. Cancer. 1990 Sep 15;66(6 Suppl):1363–1372. doi: 10.1002/1097-0142(19900915)66:14+<1363::aid-cncr2820661411>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  21. Karnik P. S., Kulkarni S., Liu X. P., Budd G. T., Bukowski R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994 Jan 15;54(2):349–353. [PubMed] [Google Scholar]
  22. Kauppila A. J., Isotalo H. E., Kivinen S. T., Vihko R. K. Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res. 1986 Oct;46(10):5380–5384. [PubMed] [Google Scholar]
  23. King W. J., Greene G. L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 1984 Feb 23;307(5953):745–747. doi: 10.1038/307745a0. [DOI] [PubMed] [Google Scholar]
  24. Koelle M. R., Segraves W. A., Hogness D. S. DHR3: a Drosophila steroid receptor homolog. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6167–6171. doi: 10.1073/pnas.89.13.6167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Koji T., Brenner R. M. Localization of estrogen receptor messenger ribonucleic acid in rhesus monkey uterus by nonradioactive in situ hybridization with digoxigenin-labeled oligodeoxynucleotides. Endocrinology. 1993 Jan;132(1):382–392. doi: 10.1210/endo.132.1.8419136. [DOI] [PubMed] [Google Scholar]
  26. Kokontis J., Ito K., Hiipakka R. A., Liao S. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor. 1991;1(4):271–279. [PubMed] [Google Scholar]
  27. Kokontis J., Liao S., Chang C. Transcriptional activation by TR3 receptor, a member of the steroid receptor superfamily. Receptor. 1991;1(4):261–270. [PubMed] [Google Scholar]
  28. Ladanyi M., Mulay S., Arseneau J., Bettez P. Estrogen and progesterone receptor determination in the papillary cystic neoplasm of the pancreas. With immunohistochemical and ultrastructural observations. Cancer. 1987 Oct 1;60(7):1604–1611. doi: 10.1002/1097-0142(19871001)60:7<1604::aid-cncr2820600731>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  29. Landers J. P., Spelsberg T. C. New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit Rev Eukaryot Gene Expr. 1992;2(1):19–63. [PubMed] [Google Scholar]
  30. Lindahl B., Alm P., Fernö M., Grundsell H., Norgren A., Tropé C. Relapse of endometrial carcinoma related to steroid receptor concentration, staging, histologic grading and myometrial invasion. Anticancer Res. 1986 Nov-Dec;6(6):1317–1320. [PubMed] [Google Scholar]
  31. Manning D. L., McClelland R. A., Gee J. M., Chan C. M., Green C. D., Blamey R. W., Nicholson R. I. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer. 1993;29A(10):1462–1468. doi: 10.1016/0959-8049(93)90021-7. [DOI] [PubMed] [Google Scholar]
  32. Manning D. L., Robertson J. F., Ellis I. O., Elston C. W., McClelland R. A., Gee J. M., Jones R. J., Green C. D., Cannon P., Blamey R. W. Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur J Cancer. 1994;30A(5):675–678. doi: 10.1016/0959-8049(94)90543-6. [DOI] [PubMed] [Google Scholar]
  33. Markopoulos C., Berger U., Wilson P., Gazet J. C., Coombes R. C. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J (Clin Res Ed) 1988 May 14;296(6633):1349–1351. doi: 10.1136/bmj.296.6633.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Masai M., Sumiya H., Akimoto S., Yatani R., Chang C. S., Liao S. S., Shimazaki J. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate. 1990;17(4):293–300. doi: 10.1002/pros.2990170405. [DOI] [PubMed] [Google Scholar]
  35. McCarty K. S., Jr, Miller L. S., Cox E. B., Konrath J., McCarty K. S., Sr Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716–721. [PubMed] [Google Scholar]
  36. McClelland R. A., Berger U., Miller L. S., Powles T. J., Coombes R. C. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol. 1986 Aug;4(8):1171–1176. doi: 10.1200/JCO.1986.4.8.1171. [DOI] [PubMed] [Google Scholar]
  37. McClelland R. A., Finlay P., Walker K. J., Nicholson D., Robertson J. F., Blamey R. W., Nicholson R. I. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res. 1990 Jun 15;50(12):3545–3550. [PubMed] [Google Scholar]
  38. McClelland R. A., Wilson D., Leake R., Finlay P., Nicholson R. I. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. Eur J Cancer. 1991;27(6):711–715. doi: 10.1016/0277-5379(91)90171-9. [DOI] [PubMed] [Google Scholar]
  39. McGuire W. L., Chamness G. C., Fuqua S. A. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):243–247. doi: 10.1016/0960-0760(92)90214-4. [DOI] [PubMed] [Google Scholar]
  40. Metzger S., Halaas J. L., Breslow J. L., Sladek F. M. Orphan receptor HNF-4 and bZip protein C/EBP alpha bind to overlapping regions of the apolipoprotein B gene promoter and synergistically activate transcription. J Biol Chem. 1993 Aug 5;268(22):16831–16838. [PubMed] [Google Scholar]
  41. Miyamoto K. K., McSherry S. A., Dent G. A., Sar M., Wilson E. M., French F. S., Sharief Y., Mohler J. L. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol. 1993 May;149(5):1015–1019. doi: 10.1016/s0022-5347(17)36284-5. [DOI] [PubMed] [Google Scholar]
  42. Mobbs B. G., Liu Y. Immunohistochemical localization of progesterone receptor in benign and malignant human prostate. Prostate. 1990;16(3):245–251. doi: 10.1002/pros.2990160308. [DOI] [PubMed] [Google Scholar]
  43. Nicholson R. I., Bouzubar N., Walker K. J., McClelland R., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer. 1991;27(7):908–913. doi: 10.1016/0277-5379(91)90145-4. [DOI] [PubMed] [Google Scholar]
  44. Nicholson R. I., McClelland R. A., Finlay P., Eaton C. L., Gullick W. J., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 1993;29A(7):1018–1023. doi: 10.1016/s0959-8049(05)80215-1. [DOI] [PubMed] [Google Scholar]
  45. Nicholson R. I., McClelland R. A., Gee J. M., Manning D. L., Cannon P., Robertson J. F., Ellis I. O., Blamey R. W. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat. 1994 Jan;29(1):117–125. doi: 10.1007/BF00666187. [DOI] [PubMed] [Google Scholar]
  46. Nicholson R. I., McClelland R. A., Gee J. M., Manning D. L., Cannon P., Robertson J. F., Ellis I. O., Blamey R. W. Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res. 1994 Apr 1;54(7):1684–1689. [PubMed] [Google Scholar]
  47. Nicholson R. I., Walker K. J., Davies P. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer. Cancer Surv. 1986;5(3):463–486. [PubMed] [Google Scholar]
  48. O'Malley B. W., Tsai M. J. Molecular pathways of steroid receptor action. Biol Reprod. 1992 Feb;46(2):163–167. doi: 10.1095/biolreprod46.2.163. [DOI] [PubMed] [Google Scholar]
  49. Ozono K., Sone T., Pike J. W. The genomic mechanism of action of 1,25-dihydroxyvitamin D3. J Bone Miner Res. 1991 Oct;6(10):1021–1027. doi: 10.1002/jbmr.5650061002. [DOI] [PubMed] [Google Scholar]
  50. Palmer D. C., Muir I. M., Alexander A. I., Cauchi M., Bennett R. C., Quinn M. A. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol. 1988 Sep;72(3 Pt 1):388–393. [PubMed] [Google Scholar]
  51. Parker M. G. Structure and function of nuclear hormone receptors. Semin Cancer Biol. 1990 Feb;1(1):81–87. [PubMed] [Google Scholar]
  52. Power R. F., Mani S. K., Codina J., Conneely O. M., O'Malley B. W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991 Dec 13;254(5038):1636–1639. doi: 10.1126/science.1749936. [DOI] [PubMed] [Google Scholar]
  53. Press M. F., Nousek-Goebl N. A., Bur M., Greene G. L. Estrogen receptor localization in the female genital tract. Am J Pathol. 1986 May;123(2):280–292. [PMC free article] [PubMed] [Google Scholar]
  54. Ravdin P. M., Green S., Dorr T. M., McGuire W. L., Fabian C., Pugh R. P., Carter R. D., Rivkin S. E., Borst J. R., Belt R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1284–1291. doi: 10.1200/JCO.1992.10.8.1284. [DOI] [PubMed] [Google Scholar]
  55. Rayter Z. Steroid receptors in breast cancer. Br J Surg. 1991 May;78(5):528–535. doi: 10.1002/bjs.1800780506. [DOI] [PubMed] [Google Scholar]
  56. Rio M. C., Chambon P. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells. 1990 Aug-Sep;2(8-9):269–274. [PubMed] [Google Scholar]
  57. Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat. 1990 Jul;16(1):3–13. doi: 10.1007/BF01806570. [DOI] [PubMed] [Google Scholar]
  58. Sacks N. P., Smith K., Norman A. P., Greenall M., LeJeune S., Harris A. L. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. Eur J Cancer. 1993;29A(3):426–428. doi: 10.1016/0959-8049(93)90401-z. [DOI] [PubMed] [Google Scholar]
  59. Sadi M. V., Walsh P. C., Barrack E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991 Jun 15;67(12):3057–3064. doi: 10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  60. Schoenberg M. P., Hakimi J. M., Wang S., Bova G. S., Epstein J. I., Fischbeck K. H., Isaacs W. B., Walsh P. C., Barrack E. R. Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun. 1994 Jan 14;198(1):74–80. doi: 10.1006/bbrc.1994.1011. [DOI] [PubMed] [Google Scholar]
  61. Shi S. R., Key M. E., Kalra K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. doi: 10.1177/39.6.1709656. [DOI] [PubMed] [Google Scholar]
  62. Snead D. R., Bell J. A., Dixon A. R., Nicholson R. I., Elston C. W., Blamey R. W., Ellis I. O. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology. 1993 Sep;23(3):233–238. doi: 10.1111/j.1365-2559.1993.tb01195.x. [DOI] [PubMed] [Google Scholar]
  63. Stopera S. A., Bird R. P. Nuclear retinoic acid "orphan" receptors: progress towards an understanding of the new complexities in retinoid metabolism. Prog Food Nutr Sci. 1991;15(4):219–230. [PubMed] [Google Scholar]
  64. Suzuki H., Sato N., Watabe Y., Masai M., Seino S., Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol. 1993 Dec;46(6):759–765. doi: 10.1016/0960-0760(93)90316-o. [DOI] [PubMed] [Google Scholar]
  65. Tran P., Zhang X. K., Salbert G., Hermann T., Lehmann J. M., Pfahl M. COUP orphan receptors are negative regulators of retinoic acid response pathways. Mol Cell Biol. 1992 Oct;12(10):4666–4676. doi: 10.1128/mcb.12.10.4666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Wakeling A. E. Steroid antagonists as nuclear receptor blockers. Cancer Surv. 1992;14:71–85. [PubMed] [Google Scholar]
  67. Walker K. J., Bouzubar N., Robertson J., Ellis I. O., Elston C. W., Blamey R. W., Wilson D. W., Griffiths K., Nicholson R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res. 1988 Nov 15;48(22):6517–6522. [PubMed] [Google Scholar]
  68. Walker K. J., McClelland R. A., Candlish W., Blamey R. W., Nicholson R. I. Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer. 1992;28(1):34–37. doi: 10.1016/0959-8049(92)90379-g. [DOI] [PubMed] [Google Scholar]
  69. Wernert N., Gerdes J., Loy V., Seitz G., Scherr O., Dhom G. Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Arch A Pathol Anat Histopathol. 1988;412(4):387–391. doi: 10.1007/BF00750267. [DOI] [PubMed] [Google Scholar]
  70. Whittle I. R., Hawkins R. A., Miller J. D. Sex hormone receptors in intracranial tumours and normal brain. Eur J Surg Oncol. 1987 Aug;13(4):303–307. [PubMed] [Google Scholar]
  71. Wu C. W., Tsay S. H., Chang T. J., Chang H. M., Hsieh M. C., Lui W. Y., P'eng F. K., Chi C. W. Clinicopathologic comparisons between estrogen receptor-positive and -negative gastric cancers. J Surg Oncol. 1992 Dec;51(4):231–235. doi: 10.1002/jso.2930510406. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES